Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes
about
Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewInnate Immune Signaling Activated by MDR Bacteria in the AirwayTree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse.Effective immunosuppression with dexamethasone phosphate in the Galleria mellonella larva infection model resulting in enhanced virulence of Escherichia coli and Klebsiella pneumoniaeVirulence and Genomic Feature of a Virulent Klebsiella pneumoniae Sequence Type 14 Strain of Serotype K2 Harboring blaNDM-5 in China.Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniae.Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing.Recent developments in severe sepsis research: from bench to bedside and back.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Galleria mellonella as a model system to assess the efficacy of antimicrobial agents against Klebsiella pneumoniae infection.Deep transcriptome profiling of clinical Klebsiella pneumoniae isolates reveals strain and sequence type-specific adaptation.All models are wrong, but some are useful: Averting the 'microbial apocalypse'.Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.Evaluating Different Virulence Traits of Klebsiella pneumoniae Using Dictyostelium discoideum and Zebrafish Larvae as Host Models.Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia.
P2860
Q26796605-522AE7BB-3160-48B3-9518-100576B0C412Q36422470-10AC6450-72CC-4FA0-8EBF-BE94FA0ECF20Q36571839-AABE4F03-8821-4CFF-A03D-21FD226073C9Q37080651-2A5CB21B-F7B3-4462-8B9F-52A99FA35A94Q37716730-201631BF-90CB-41FE-A16A-9C4585E335D2Q38683581-2CC04414-9C70-4F39-8714-3FB3FDA4A102Q38686917-A853CABF-350E-4EC7-8610-0C0393C1FF0CQ38724278-511D7CAC-F3FE-4CC5-A7B9-D4F6BDB67FABQ38741453-8B9988FA-D6FB-4372-86E4-E648C78FDAA2Q40654623-A2502988-36FB-4A76-9AD6-6F99A417BAE1Q41059926-25BFC09D-2EB0-442C-A5FE-64D401B42574Q42909817-6E0ED927-D196-484A-AFC8-2E52187713CAQ46152898-EA4CAE3A-B700-4415-8949-D61784E21031Q51149459-148056CF-0EEE-484E-A9F3-41F1CEC88B25Q53793889-CF9B1AC8-58E5-4D9F-820E-3BA8E2080510
P2860
Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quantifying the clinical virul ...... translate to patient outcomes
@en
Quantifying the clinical virul ...... translate to patient outcomes.
@nl
type
label
Quantifying the clinical virul ...... translate to patient outcomes
@en
Quantifying the clinical virul ...... translate to patient outcomes.
@nl
prefLabel
Quantifying the clinical virul ...... translate to patient outcomes
@en
Quantifying the clinical virul ...... translate to patient outcomes.
@nl
P2093
P2860
P356
P1476
Quantifying the clinical virul ...... translate to patient outcomes
@en
P2093
Grace Barajas
M Renee Advincula
Michael Malczynski
Milena M McLaughlin
P2860
P2888
P356
10.1186/1471-2334-14-31
P577
2014-01-15T00:00:00Z
P5875
P6179
1006946133